Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics (NCT01610154), a na phase 4 study. The primary outcome is Change From Baseline in Hemoglobin A1c (HbA1c).

2. Clinical Question

3. Trial Design

This is a completed Phase 4 study recorded as a single-group trial of sitagliptin treatment. The registry lists enrollment as 85. Allocation is recorded as not applicable, and masking as none. No separate comparator arm is described, so the study is not a randomized comparison and its treatment group cannot be compared with a contemporaneous control group in the registry record.

The recorded study start is 2012-10 and primary completion is 2014-08. The primary outcome is change from baseline in HbA1c, measured over baseline to 12 weeks. The registry describes the primary outcome as a mean with standard deviation as its dispersion measure. It also names changes in fasting and postprandial plasma glucose, insulin sensitivity, pancreatic beta cell function, and pancreatic alpha cell function among secondary outcomes. Several of these outcomes are also listed for people with different BMI.

The study objectives describe questions about the effects of sitagliptin on glucagon secretion, insulin secretion, insulin resistance, and glucose control in Chinese people with type 2 diabetes. They also raise the possibility that glucagon release contributes over 30% to hyperglycemia and ask whether responses differ between BMI categories. These statements define questions of interest; they do not establish that the proposed effects or differences were observed.

The registry does not report the treatment regimen details, eligibility criteria, participant flow, or the number included in each outcome analysis. It does not describe a control condition, randomization procedure, or masking beyond the entries noted above. Although the study status is completed, that status alone does not provide outcome results or show how complete the outcome data were.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in Hemoglobin A1c (HbA1c), measured over Baseline to 12 weeks.

Hemoglobin A1c (HbA1c) is a blood measure used to assess glycemia over a longer period than a single glucose measurement. It is commonly used as an outcome in studies of glucose regulation because it can capture changes in average glycemia over time. This is general context about the measure, not a finding from this trial.

The primary outcome is defined as change from baseline in HbA1c, with the timeframe stated as baseline to 12 weeks. A change outcome compares a participant's measurement at follow-up with that participant's baseline measurement. The registry identifies the summary parameter as a mean and the dispersion measure as a standard deviation. The record does not state the observed mean change, its standard deviation, a confidence interval, or an analysis result. It therefore does not show the size or precision of the primary outcome estimate.

In a single-group study, a baseline-to-follow-up change can describe how measurements differed during the study period, but it does not by itself isolate the effect of treatment from other influences over time. Without a control group, the primary endpoint cannot support a randomized between-group treatment comparison. The outcome definition is useful for describing change; its interpretation depends on the missing result and on the study's non-comparative design.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is a continuous measure summarized as a mean, with standard deviation specified as the measure of dispersion. A mean describes the arithmetic center of observed values. The standard deviation describes how spread out individual measurements are around that mean. It is not the same as a standard error or a confidence interval: the standard deviation concerns variation among measurements, whereas the standard error concerns uncertainty in an estimated mean.

What does a change score represent?

A change-from-baseline outcome uses a follow-up measurement in relation to the participant's own baseline measurement. This can account for differences in starting values when describing how measurements shifted over time. The resulting mean change summarizes the average shift in the analyzed group; the standard deviation of change scores describes variation in those shifts among participants. The registry record specifies change from baseline in HbA1c over baseline to 12 weeks, but does not give the measurements, calculated change, or the number analyzed.

Repeated measurements on the same participant are generally related rather than independent. In general, an analysis of change or a model of repeated measurements should account for that relationship. The registry record does not report which method was used, whether the analysis used change scores or another approach, or how baseline values were handled. No method can be attributed to the study on the basis of the outcome description alone.

How should a confidence interval be read?

In general, a confidence interval expresses uncertainty around an estimated quantity under the assumptions of the analysis. A narrow interval indicates greater precision than a wide interval, while an interval that spans values of different practical interpretations may leave substantial uncertainty. A confidence interval is not a guarantee that the true value lies within its limits. The registry record does not report a confidence interval for HbA1c change or for the listed secondary outcomes, so it does not allow this kind of precision assessment.

A p-value, when reported, measures how incompatible the observed data are with a specified null model, given the analysis assumptions. It does not measure the size or clinical importance of an effect, and it does not give the probability that the null hypothesis is true. No p-value or other inferential analysis for the outcomes is reported in the registry record. There is therefore no reported significance result to interpret.

Why does the study structure matter?

This is a single-group study with no separate control group recorded. In general, an observed change over time can reflect treatment as well as other influences, including natural fluctuation, concurrent care, changes in behavior, measurement conditions, or selection into follow-up. A randomized control group can help separate treatment-related differences from such influences. The registry record does not document a randomized comparison, and the listed allocation is not applicable. The study's within-group outcome descriptions, even if available, would not have the same causal interpretation as a randomized between-group contrast.

The record lists sample-size planning assumptions that describe a hypothetical two-arm illustration: a two-sided significance level of 0.05, equal allocation between arms, a normal approximation, and an effect defined as a stated fraction of the observed effect. These assumptions describe a planning calculation, not the trial's recorded single-group design. Any planning illustration based on them is not an observed power estimate and does not establish that the trial was designed or analyzed according to those assumptions. The registry record does not report a trial-specific sample-size justification or the numerical planning outputs.

Over-dispersion is a general issue for count outcomes when the observed variability exceeds what a basic count model assumes. In such settings, standard errors and confidence intervals from an overly restrictive model may be too small. The primary outcome in this record is continuous HbA1c, not a count endpoint, and no count-model analysis is reported. This general concept does not identify a method used in the study.

For adverse events, a count of affected participants is a descriptive safety summary. Its interpretation depends on definitions, observation time, completeness of follow-up, and whether events are attributed to treatment. The record gives at-risk and affected counts for serious and other adverse events, but does not describe those details or report event terms. The counts alone do not estimate a comparative risk because no control group is listed.

Overall, the registry identifies the outcome type and descriptive summary for the primary endpoint but does not report the inferential method, estimates, uncertainty measures, or analysis population. Statistical interpretation must remain limited to what the record actually reports; design labels and outcome titles cannot substitute for numerical results.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Sitagliptin")
n   <- c(84)
m   <- c(-1.08)
sp  <- c(0.13)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Sitagliptin  84  -1.080  0.130  -1.108  -1.052

11. Multiplicity, Missing Data and Analysis Populations

The registry lists nine outcome measures, including primary HbA1c change and secondary measures of fasting and postprandial plasma glucose, insulin sensitivity, and pancreatic beta and alpha cell function. Some secondary outcomes are also specified for patients with different BMI. Considering several outcomes and subgroup questions raises a general multiplicity issue: the more comparisons examined, the more opportunities there may be to observe an apparently notable result by chance. The registry record does not report a multiplicity adjustment, a hierarchy for interpreting outcomes, or a prespecified strategy for subgroup testing.

The record lists zero analysis entries. It does not report which participants were included in each outcome analysis, whether analyses followed an intention-to-treat approach, or how exclusions were handled. Missing-data methods, reasons for missing measurements, and the completeness of follow-up for the primary or secondary outcomes are not reported in the registry record. The registered enrollment of 85 does not establish how many participants contributed data to a particular outcome.

The record also does not report whether any analyses were planned at interim points or how any deviations from the intended analysis were handled. These details are not reported in the registry record. Without the analysis population, missing-data handling, and multiplicity approach, the robustness of any outcome analysis cannot be assessed. Since numerical outcome estimates are also absent, the record does not permit an appraisal of the impact of these choices on the findings.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

Most frequent non-serious adverse event terms

For the sitagliptin treatment group, the registry record lists 84 at risk for serious adverse events and 0 affected. It also lists 84 at risk for other adverse events and 8 affected. These are counts as recorded; no percentages or comparative estimates are reported. The record does not identify the terms for serious events, and deaths are not reported in the registry record.

A zero recorded serious-event count does not establish that serious harms are impossible or that every event was captured. Interpretation depends on what qualified as an event, how events were collected, the observation period, completeness of follow-up, and whether events were judged related to treatment. Those details are not reported in the registry record. The entry for other adverse events similarly does not provide event types, severity, timing, or attribution.

Because the trial is listed as single-group and no comparator is recorded, these safety counts cannot show whether event occurrence differed from what would have been observed under another treatment or without the study treatment. They are descriptive figures for the recorded treatment group, not a comparative safety estimate.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a completed Phase 4, single-group study of sitagliptin was registered with HbA1c change from baseline to 12 weeks as its primary outcome. It also records objectives concerning glucagon secretion, glucose regulation, insulin secretion and resistance, pancreatic alpha and beta cell function, and possible differences by BMI. Those details describe the study's questions and structure.

The record does not report numerical results or analyses for the primary or secondary outcomes. It therefore does not show whether HbA1c, glucose measures, insulin sensitivity, or pancreatic cell function changed. It also does not establish whether changes differed between BMI categories or whether glucagon release contributed over 30% to hyperglycemia. An objective stated in a registry is not evidence that the proposed effect was found.

The absence of a control group is an important interpretive constraint. A reported before-and-after change in a single group would describe change during the study, but could not by itself distinguish a treatment effect from other time-related influences. The record also does not provide confidence intervals or other outcome uncertainty measures, so the precision of any effect cannot be assessed.

The safety entries report 0 serious adverse events and 8 other adverse events among 84 at risk in the treatment group. These counts are descriptive and do not support a comparison with another group. They do not by themselves establish the presence or absence of a causal safety effect, particularly because event terms and collection details are not reported.

Accordingly, the registry information supports a description of the research question, intervention, design, outcome definitions, and recorded adverse-event counts. It does not support a conclusion about the magnitude, certainty, or causal interpretation of treatment effects. Such conclusions would require reported outcome data and sufficient information about the analyses and participants contributing those data.

14. Why This Trial Matters Statistically

This trial is statistically notable because its questions about change in glucose-related measures are paired with a single-group design. A baseline measurement can provide a useful reference for describing subsequent change, but it does not supply the untreated comparison needed to distinguish treatment-associated change from change over time. Readers should keep the descriptive meaning of a within-group change separate from the causal meaning of a controlled treatment contrast.

The registry's outcome set also spans several related domains: HbA1c, fasting and postprandial plasma glucose, insulin sensitivity, and pancreatic alpha and beta cell function. It includes outcomes framed around different BMI categories. This breadth can be useful for describing related biological and clinical questions, but it also makes clear reporting of analysis plans, outcome priorities, and multiplicity procedures important. Those details are not reported in the registry record.

Precision matters as much as direction. A mean change without a standard error or confidence interval would not show how uncertain the estimate is. Here, the outcome estimates and uncertainty measures are not reported, and the registry lists zero analysis entries. Thus, the central statistical question is not whether an estimate crosses a significance threshold; the record does not supply an estimate to evaluate. The missing results prevent assessment of effect size and precision.

The safety figures illustrate a related point: descriptive counts need context about event definitions, follow-up, and comparison groups. The registry records events in the treatment group but does not report event terms or a control group. These entries cannot be read as a comparative risk analysis. Overall, the record is useful for identifying the study's intended questions and design constraints, while its reporting gaps limit what can be inferred about outcomes.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpretation is that outcome estimates and analyses are not reported in the registry record. The primary HbA1c outcome is named, but its mean change, standard deviation, and uncertainty are absent. The same reporting gap applies to the secondary outcomes. The record therefore cannot establish the direction or size of the measured changes, their precision, or whether analyses supported the stated research aims.

The single-group design and lack of a recorded comparator limit causal interpretation independently of the missing results. Even if within-group changes were available, they would not distinguish treatment effects from other changes over time. The registry lists no random allocation and no masking. These design features mean that a like-for-like control comparison is not documented.

Important details about conduct and analysis are also not reported in the registry record. These include eligibility criteria, treatment regimen details, participant flow, outcome-specific analysis populations, missing-data handling, analysis methods, and multiplicity procedures. The record does not give the numbers contributing to the BMI-specific outcomes, nor does it report whether subgroup analyses were prespecified. Without these details, completeness and potential bias in the outcome analyses cannot be assessed.

The safety information is limited to at-risk and affected counts. Event names, definitions, timing, severity, attribution, and follow-up completeness are not reported. Deaths are not reported in the registry record. The counts should therefore be treated as a limited descriptive account, not as a full safety evaluation or comparative estimate.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics — NCT01610154.
• Registry record last updated 2017-05-11; status last verified 2017-04.
• Results first posted 2017-04-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes a completed Phase 4, single-group study of sitagliptin in Chinese people with type 2 diabetes. Enrollment is listed as 85; the recorded start is 2012-10 and primary completion is 2014-08. Allocation is listed as not applicable and masking as none.

The primary outcome is change from baseline in HbA1c over baseline to 12 weeks, summarized as a mean with standard deviation. Secondary outcomes concern glucose measures, insulin sensitivity, and pancreatic alpha and beta cell function, including outcomes by BMI. The registry record does not report outcome estimates or analyses.

For the treatment group, the record lists 0 serious adverse events among 84 at risk and 8 other adverse events among 84 at risk. Serious event terms and deaths are not reported in the registry record. The single-group design and missing outcome analyses limit interpretation of both efficacy-related questions and comparative safety.